Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

inhaled treatment

- PMLiVE

UPDATED: J&J expands US partnership for coronavirus treatments

Expands on exisiting alliance announced last week

- PMLiVE

Four more coronavirus cases confirmed in the UK

Secretary of State declares outbreak a “serious and imminent threat”

- PMLiVE

GSK and Gilead join global efforts to tackle novel coronavirus

Confirmed cases rise to over 17,000 in China

- PMLiVE

UK confirms first cases of coronavirus as global concerns mount

Pharma industry steps up its efforts to develop therapeutics for infection

- PMLiVE

J&J begins search for a coronavirus vaccine as confirmed cases rise

Death toll has now reached 170, with 7,711 confirmed cases in China

- PMLiVE

New coronavirus sees drug developers scramble to develop a vaccine

Researchers work to combat emerging threat

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Study finds no problems switching from Remicade to biosimilar

Findings look to dispel ‘biosimilar resistance’ and encourage greater uptake

- PMLiVE

J&J is to appeal Remicade patent ruling in US

As Pfizer is poised to bring biosimilar version to market

- PMLiVE

Remicade safe from biosimilar competition this year, says J&J

Will defend the blockbuster’s US patents should Celltrion's Inflectra launch in 2016

- PMLiVE

FDA approves first Remicade biosimilar

Pfizer-Celltrion's Inflectra becomes the second biosimilar to be licensed in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links